Key points are not available for this paper at this time.
ABSTRACT This study aimed to assess the impact of Ganoderma lucidum supplementation (200–11,200 mg/day, 1–24 weeks) on health‐related indices in populations including healthy, at‐risk, and chronic disease individuals. A systematic review and meta‐analysis were conducted using data from EMBASE, PubMed, Web of Science, and Scopus up to August 2024. Pooled analysis of 17 randomized controlled trials (RCTs) involving 971 participants revealed that Ganoderma lucidum supplementation demonstrated significant reductions in body mass index (BMI) (Weighted Mean Difference WMD = −0.43; 95% Confidence Interval CI: −0.77, −0.10; p = 0.011), creatinine (WMD = −0.14; 95% CI: −0.27, −0.02; p = 0.028), glutathione peroxidase (GPx) (WMD = 2.29; 95% CI: 1.67, 2.92; p < 0.001), and heart rate (HR) (WMD = −3.92; 95% CI: −7.45, −0.40; p = 0.029). No significant effects were observed on body fat, waist circumference, blood pressure, fasting glucose, lipid profile, inflammatory markers, or liver enzymes. Subgroup analyses indicated effects varied by health condition, dosage, duration, and age. Subgroup analyses revealed variations in the effects of Ganoderma supplementation based on health conditions, dosage, intervention duration, age at intervention, country, sample size, and publication year. Significant improvements were observed in BMI, TC, creatinine, and MDA in specific subgroups, such as those receiving lower doses (< 1400 mg/day) or those aged < 50 years. The GRADE profile for Ganoderma supplementation evaluated the certainty of the outcomes and indicated that the quality of evidence was very low across all outcomes. Ganoderma lucidum supplementation may have modest effects on certain health indices, but the evidence is limited by very low quality.
Jafari et al. (Sun,) studied this question.